Factors affecting bleeding risk during anticoagulant therapy in patients with atrial fibrillation: Observations from the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Study

American Heart Journal

Volumn 149, Issue 4, 2005, Pages 650-656

  DiMarco, John P ^a   Flaker, Gregory ^b   Waldo, Albert L ^b   Corley, Scott D ^b   Greene, H Leon ^b   Safford, Robert E ^b   Rosenfeld, Lynda E ^b   Mitrani, Gladys ^b   Nemeth, Margit ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b Box 800158 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; WARFARIN;

ADULT; AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG USE; EPISTAXIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART RHYTHM; HEMATURIA; HUMAN; INCIDENCE; KIDNEY DISEASE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; STROKE; SUBARACHNOID HEMORRHAGE; SUBDURAL HEMATOMA;

EID: 17044428901     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.11.015     Document Type: Article

References (32)

1. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham study Stroke 22 1991 983 988
2. G.W. Albers, J.E. Dalen, and A. Laupacis Antithrombotic therapy in atrial fibrillation Chest 119 2001 194S 206S
3. V. Fuster, L.E. Ryden, and R.W. Asinger Management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee on Practice Guidelines and Policy Conferences (Committee to develop guidelines for the management of atrial fibrillation) J Am Coll Cardiol 104 2001 2118 2150
4. Atrial Fibrillation Investigators Risk factors for stroke and efficacy of anti-thrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials Arch Intern Med 154 1994 1449 1457
5. Stroke Prevention in Atrial Fibrillation Investigators Stroke prevention in atrial fibrillation study: final results Circulation 84 1991 527 539
6. S.J. Connolly, A. Laupacis, and M. Gent Canadian Atrial Fibrillation Anticoagulation (CAFA) Study J Am Coll Cardiol 18 1991 349 355
7. Stroke Prevention in Atrial Fibrillation Investigators Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study Lancet 343 1994 687 691
8. P. Petersen, G. Boysen, and J. Godtfredsen Placebo-controlled randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK study Lancet 1 1989 175 178
9. EAFT (European Atrial Fibrillation Trial) Study Group Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke: EAFT (European Atrial Fibrillation Trial) Study Group Lancet 342 1993 1255 1262
10. Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation N Engl J Med 322 1990 1505 1511
11. Stroke Prevention in Atrial Fibrillation Investigators Bleeding during antithrombotic therapy in patients with atrial fibrillation Arch Intern Med 156 1996 409 416
12. M.N. Levine, G. Raskob, and S. Landefeld Hemorrhagic complications of anticoagulant treatment Chest 119 2001 108S 121S
13. Executive Steering Committee on behalf of the Sportif Investigators Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial Lancet 362 2003 1691 1698
14. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators A comparison of rate control and rhythm control in patients with atrial fibrillation N Engl J Med 347 2002 1825 1833
15. The AFFIRM Investigators Baseline characteristics of patients with atrial fibrillation: the AFFIRM study Am Heart J 143 2002 991 1001
16. G.W. Albers Atrial fibrillation and stroke. Three new studies, three remaining questions Arch Intern Med 154 1994 1443 1448
17. E.M. Hylek, and D.E. Singer Risk factors for intracranial hemorrhage in outpatients taking warfarin Ann Intern Med 120 1994 897 902
18. A.S. Go, E.M. Hylek, and K.A. Phillips Implications of stroke risk criteria on the anticoagulation decision in nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study Circulation 102 2000 11 13
19. A.S. Go, E.M. Hylek, and L.H. Borowsky Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study Ann Intern Med 131 1999 927 934
20. S.D. Fihn, C.M. Callahan, and D.C. Martin The risk and severity of bleeding complications in elderly patients treated with warfarin Ann Intern Med 124 1996 970 979
21. D.A. McMahan, D.M. Smith, and M.A. Carey Risk of major hemorrhage for outpatients treated with warfarin J Gen Intern Med 13 1998 311 316
22. M. Copland, I. Walker, and R.C. Tait Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation Arch Intern Med 161 2001 2125 2128
23. P.D. Stein, H.I. Bussey, and J.E. Dalen Antithrombotic therapy in patients with mechanical and prosthetic heart valve Chest 119 2001 220S 227S
24. L.D. Fiore, M.D. Ezekowitz, and M.T. Brophy Department of Veteran Affairs cooperative studies program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction. Primary results of the CHAMP study Circulation 105 2002 557 563
25. L.D. Heimark, L. Wienkers, and K. Kunze The mechanism of the interaction between amiodarone and warfarin in humans Clin Pharmacol Ther 51 1992 398 407
26. N.Z. Kerin, R.D. Blevins, and L. Goldman The incidence, magnitude, and time course of the amiodarone-warfarin interaction Arch Intern Med 148 1988 1779 1781
27. C.A. Sanoski, and J.L. Bauman Clinical observations with the warfarin/amiodarone interaction: dosing relationships with long-term therapy Chest 121 2002 19 23
28. R.E. Kates, Y.G. Yee, and E.B. Kirsten Interaction between warfarin and propafenone in healthy volunteer subjects Clin Pharmacol Ther 42 1987 305 311
29. J. Hirsh, V. Fuster, and J. Ansell American Heart Association/American College of Cardiology Foundation guide to warfarin therapy J Am Coll Cardiol 41 2003 1633 1655
30. C. Wehinger, C. Stolberger, and T. Langer Evaluation of risk factors for stroke/embolism and of complications due to anticoagulant therapy in atrial fibrillation Stroke 32 2001 2246 2252
31. C. van Walraven, R.G. Hart, and G.A. Wells A clinical prediction rule to identify patients with atrial fibrillation and a low risk for stroke while taking aspirin Arch Intern Med 163 2003 936 943
32. C. van Walraven, R.G. Hart, and D.E. Singer Oral anticoagulants vs. aspirin in nonvalvular atrial fibrillation. An individual patient meta-analysis JAMA 288 2002 2441 2448